

Rheumatoid arthritis (update) Committee meeting 4

Date: 30/01/2017

Location: Boardroom, NGC, 180 Great Portland Street, London, W1W 5QZ

Minutes: Confirmed

NICE National Institute for
Health and Care Excellence

Committee members present:	
Stephen Ward (SW, Chair)	(Present for notes 1–5)
Ann Bevan (ABe)	(Present for notes 1–5)
Ailsa Bosworth (ABo)	(Present for notes 1–5)
Jennie Jones (JJ)	(Present for notes 1–5)
Bruce Kirkham (BK)	(Present for notes 1–5)
Hilary McKee (HMK)	(Present for notes 1–4d)
Frank McKenna (FMK)	(Present for notes 1–5)
Anupama Nandagudi (AN)	(Present for notes 1–5)
Benjamin Parker (BP)	(Present for notes 1–5)
Heidi Siddle (HS)	(Present for notes 1–5)
Louise Warburton (LW)	(Present for notes 1–5)

In attendance:		
Caroline Keir (CK)	Guideline Commissioning Manager, NICE	(Present for notes 1–5)
Alex Allen (AA)	Senior Research Fellow, NGC	(Present for notes 1–5)
Joanne Ashe (JA)	Senior Information Scientist, NGC	(Present for notes 4d–5)
Serena Carville (SC)	Guideline Lead/Associate Director, NGC	(Present for notes 1–5)
Meredith Faust (MF)	Document Editor/Process Assistant, NGC	(Present for notes 1–5)
Lefteris Floros (LF)	Health Economist, NGC	(Present for notes 1–5)
Sophia Kemmis Betty (SKB)	Senior Health Economist, NGC	(Present for notes 1–4a)

Ben Pordes (BPO)	Acting Senior Project Manager, NGC	(Present for notes 1–5)
Jacqui Real (JR)	Senior Research Fellow, NGC	(Present for notes 1–5)

Apologies:

Vicky Chamberlain (VC)	Rheumatology Nurse Specialist
Martin Harker (MH)	Senior Health Economist, NGC

1. Welcome and objectives for the meeting

The Chair welcomed the committee members and attendees to the fourth meeting on rheumatoid arthritis. The committee members and attendees introduced themselves.

No members of the public asked to observe the meeting.

The Chair informed the committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting, which included the following rheumatoid arthritis subjects: treat-to-target, short-term steroid use (remission induction) and analgesics.

2. Confirmation of matter under discussion, and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was treat-to-target, short-term steroid use (remission induction) and analgesics.

The Chair asked everyone to declare verbally any interests that have arisen since the last meeting.

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Ailsa Bosworth	Lay member	NRAS funding received 'in kind' from Sandoz for video to be made in March.	Non-personal financial non-specific	Declare and participate
Bruce Kirkham	Consultant Rheumatologist,	Institutional funding received	Non-personal financial non-	Declare and participate

	Guy's & St Thomas' NHS Foundation Trust	by Guy's and St Thomas' NHS Foundation Trust Rheumatology Department in conjunction with Keele University from Eli Lilly, Ltd. to support an investigator partnership analysis of RA uses of routine care. BK is PI.	specific	
		Second author on Corkill 1990 study used in the short-term steroid use (remission induction) evidence review.	Personal non-financial specific	Declare and participate
Anupama Nandagudi	Consultant Rheumatologist, Basildon and Thurrock University Hospital NHS Trust	Received funding from Internis for a talk on osteoporosis to be given locally to pharmacists and GPs.	Non-personal financial non-specific	Declare and participate
		IMS – Market research on drug rep interactions £25.	Non-personal financial non-specific	Declare and participate
		Market research for SERMOT – systemic sclerosis and interstitial lung disease (ILD) £75.	Non-personal financial non-specific	Declare and participate
Benjamin Parker	Consultant Rheumatologist, Kellgren Centre for Rheumatology, Manchester	December 2016 – Chair of 'Cosentyx and Psoriatic arthritis – AXSPA'	Non-personal financial non-specific	Declare and participate

	Royal Infirmary; Honorary Clinical Senior Lecturer, Centre for Musculoskeletal Research, University of Manchester	meeting; sponsored by Novartis. Honorarium received.		
		January 2017 – Chair of ‘Impact of DevoManc on Rheumatology Services in Greater Manchester’; sponsored by Pfizer. Honorarium received.	Non-personal financial non-specific	Declare and participate
Heidi Siddle	Principal Podiatrist, Leeds Teaching Hospitals NHS Trust; and Associate Professor, Leeds Institute of Rheumatic & Musculoskeletal Medicine	Speaker/teacher British Society for Rheumatology (BSR) Foot and Ankle course. 16–17 March, Leeds. Honorarium received from BSR.	Non-personal financial non-specific	Declare and participate
Louise Warburton	GP with special interest in Musculoskeletal Medicine, Telford Musculoskeletal Service; Associate Medical Director, Shropshire Community NHS Trust; Senior Lecturer in General Practice, Keele University and Musculoskeletal Champion	Attended EULAR meeting in Zurich on 25/01/2017 to produce guidelines on exercise in osteoarthritis and inflammatory arthritis. Flight paid by ELULAR.	Non-personal financial non-specific	Declare and participate

The Chair and a senior member of the Developer's team noted that the interests declared did not prevent the attendees from fully participating in the meeting.

3. Minutes of last meeting

The Chair asked the committee if it wanted any changes made to the minutes of the last meeting. The committee agreed that the minutes were a true and accurate account of the meeting.

The Chair confirmed that all matters arising had been completed or were in hand.

4. Presentations and Discussions

- a) JR presented the evidence for treat-to-target. LF presented the economic evidence for the treat-to-target review. The committee then discussed the issues presented in relation to this guideline.
- b) AA presented the linking evidence to recommendation for analgesics. The committee then discussed the issues presented in relation to this guideline.
- c) AA presented the evidence for short-term steroid use (remission induction). The committee then discussed the issues presented in relation to this guideline.
- d) The committee discussed the draft protocols for clinical criteria, ultrasound and monitoring of rheumatoid arthritis.
- e) BP demonstrated the use of SharePoint to the committee.

5. Any other business

None.

Date of next meeting: 07/03/2017

Location of next meeting: Boardroom, National Guideline Centre, 180 Great Portland Street, London W1W 5QZ